Elite Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
Elite Pharmaceuticals, Inc. (ELTP) reported Increase (Decrease) in Accrued Liabilities of -$3.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$3.76M, a 578.62% decline year-over-year.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $4.65M, a 5996.57% increase year-over-year.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$604.52K.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $1.57M.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2026 was $6.40M.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.51M, a 119.42% decline from fiscal 2024.
- Elite Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $7.76M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.76M 10-Q · filed 2026-08-13 | $882.02K derived: sum of 2 quarters · filed 2026-08-13 | $277.50K derived: sum of 3 quarters · filed 2026-08-13 | $1.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $4.04M derived: sum of 2 quarters · filed 2026-06-29 | $5.61M derived: sum of 3 quarters · filed 2026-06-29 | $6.40M 10-K · filed 2026-06-29 |
| 2025-12-31 | -$604.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $966.04K derived: sum of 2 quarters · filed 2026-02-17 | $1.75M 10-Q · filed 2026-02-17 | $1.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $2.36M 10-Q · filed 2025-11-14 | $2.43M derived: sum of 3 quarters · filed 2026-08-13 | $448.84K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $786.52K 10-Q · filed 2026-08-13 | $862.73K derived: sum of 2 quarters · filed 2026-08-13 | -$1.12M derived: sum of 3 quarters · filed 2026-08-13 | -$1.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $76.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$1.91M derived: sum of 2 quarters · filed 2026-06-29 | -$2.43M derived: sum of 3 quarters · filed 2026-06-29 | -$1.51M 10-K · filed 2026-06-29 |
| 2024-12-31 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | -$2.51M derived: sum of 2 quarters · filed 2026-02-17 | -$1.58M 10-Q · filed 2026-02-17 | $2.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$524.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $401.72K 10-Q · filed 2025-11-14 | $4.48M derived: sum of 3 quarters · filed 2025-11-14 | $4.12M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $926.35K 10-Q · filed 2025-08-14 | $5.01M derived: sum of 2 quarters · filed 2025-08-14 | $4.64M derived: sum of 3 quarters · filed 2025-08-14 | $7.80M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | $3.72M derived: sum of 2 quarters · filed 2025-06-30 | $6.88M derived: sum of 3 quarters · filed 2025-06-30 | $7.76M 10-K · filed 2025-06-30 |
| 2023-12-31 | -$366.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $2.80M derived: sum of 2 quarters · filed 2025-02-13 | $3.68M 10-Q · filed 2025-02-13 | |
| 2023-09-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-14 | $4.04M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $881.43K 10-Q · filed 2024-08-14 |